Muneeb Muhammad, Choi Elizabeth, Rodriguez Coralys, Goyal Kanika, Bhura Zainab, Hannoudi Ghadeer
Internal Medicine, Trinity Health Oakland/Wayne State University, Pontiac, USA.
Internal Medicine, Wayne State University School of Medicine, Detroit, USA.
Cureus. 2025 Jul 15;17(7):e88015. doi: 10.7759/cureus.88015. eCollection 2025 Jul.
Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used due to their significant anti-atherosclerotic, cardiovascular, and renoprotective benefits. However, potential adverse effects must also be considered. Here, we present a rare case of GLP-1 receptor agonist-induced thrombotic complications in a middle-aged African American female, contributing to the limited existing literature on this topic. A 55-year-old African American female with a past medical history of deceased donor renal transplantation presented with pain, swelling, and erythema localized to the left arteriovenous (AV) fistula. She also reported fever, chills, and the absence of a palpable thrill over the fistula for approximately one week before presentation. On physical examination, she exhibited significant swelling of the left upper limb with no detectable thrill over the AV fistula. Venous and arterial Doppler ultrasound of the left upper extremity revealed extensive thrombosis involving the left AV fistula, brachiocephalic vein, and both the radial and ulnar arteries. An extensive prothrombotic workup, including evaluations for inherited and acquired hypercoagulable states, was unremarkable. The only notable change in her medical regimen was a recent dose escalation of her GLP-1 receptor agonist. Given the temporal association and absence of alternative causes, the thrombosis was attributed to the GLP-1 receptor agonist, which was subsequently discontinued. No further thrombotic events occurred during follow-up. This case highlights one of the rare thrombotic events of commonly used drugs, such as GLP-1 receptor agonists. This case also underscores the importance of life-threatening events of commonly used drugs, adding to the existing literature.
胰高血糖素样肽-1(GLP-1)受体激动剂因其显著的抗动脉粥样硬化、心血管保护和肾脏保护作用而被广泛使用。然而,也必须考虑其潜在的不良反应。在此,我们报告一例中年非裔美国女性因GLP-1受体激动剂引起血栓形成并发症的罕见病例,为该主题的现有文献增添了内容。一名55岁有已故供体肾移植病史的非裔美国女性,出现局限于左动静脉内瘘的疼痛、肿胀和红斑。她还报告在就诊前约一周出现发热、寒战,且内瘘处未触及震颤。体格检查时,她左上肢明显肿胀,动静脉内瘘处未检测到震颤。左上肢动静脉多普勒超声显示广泛血栓形成,累及左动静脉内瘘、头臂静脉以及桡动脉和尺动脉。包括对遗传性和获得性高凝状态评估在内的广泛血栓前状态检查未见异常。她的治疗方案中唯一显著的变化是最近增加了GLP-1受体激动剂的剂量。鉴于时间上的关联以及无其他病因,血栓形成归因于GLP-1受体激动剂,随后停用该药物。随访期间未发生进一步的血栓事件。该病例突出了常用药物(如GLP-1受体激动剂)罕见的血栓形成事件之一。该病例还强调了常用药物危及生命事件的重要性,为现有文献增添了内容。